Status:
RECRUITING
ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank
Lead Sponsor:
Christoph Aufricht
Conditions:
Focal Segmental Glomerulosclerosis
Proteinuria
Eligibility:
All Genders
Up to 75 years
Brief Summary
Nephrotic syndrome is the clinical phenotype of a heterogeneous group of glomerular diseases that may present with varying degrees of urinary protein loss (proteinuria), dysproteinemia in the blood, f...
Detailed Description
A significant proportion of patients with nephrotic syndrome remains unresponsive to currently used therapies ("resistant nephrotic syndrome"), the majority of them with focal segmental glomeruloscler...
Eligibility Criteria
Inclusion
- Resistant to standard Immunosuppressive agents (if clinically indicated, e.g. primary/non-genetic forms)
- Persistent urinary protein-to-creatinine (UP/C) ratio \>1.0 g/g
- eGFR \> 30 ml/min per 1.73 m2
- biopsy or a disease-causing genetic mutation associated with nephrotic syndrome
Exclusion
- Inability or unwillingness to comply with repeated assessments
- Objections against participation at discretion of the investigator
- Secondary
- Patients with steroid-dependence/frequently relapsing disease (but achievement of complete remission)
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2033
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06162546
Start Date
January 1 2023
End Date
December 31 2033
Last Update
December 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Pediatric Nephrology and Gastroenterology, Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics, Medical University of Vienna, 1090 Vienna, Austria.
Vienna, Austria, 1090